EnlitenAI

EnlitenAI operates at the intersection of digital therapeutics, neurological monitoring, and connected medical devices. Its stated focus is narrower than broad remote-patient-monitoring platforms: NeuroLiten is centered first on epilepsy and seizures, with an intended path toward adjacent neurological and behavioral conditions. The proposed differentiation is the combination of continuous wearable-derived data, AI analytics, mobile and web access, and a healthcare data architecture designed for personalized monitoring. Relevant market comparison points include Empatica, which focuses on wearable biosensing and digital biomarkers, NeuroPace, which develops implantable technology for epilepsy, and Biofourmis, which applies analytics to remote care and digital therapeutics. These companies indicate the breadth of the competitive landscape, but the available profile does not establish direct commercial competition or equivalent regulatory status. EnlitenAI’s $605,000 in disclosed funding and 1–10 employee range place it at an early development stage relative to more capitalized health-technology companies. Its potential advantage is disease-specific workflow design for epilepsy; its main constraints are limited evidence of scale, clinical validation, regulatory clearance, and market adoption.

EnlitenAI’s trajectory shows progression from formation to early product and intellectual-property development, but not yet demonstrable commercial scale. The company was founded on Dec 8, 2020 and received non-equity assistance associated with Aurelia Ventures on Jul 21, 2021. A $150,000 grant followed on May 18, 2022, and the company announced a $455,000 pre-seed round on May 1, 2023. During this period, the leadership group expanded beyond founder and CEO Himanshu Misra: Abhiroop Gandhi is listed as COO from 2022-07, and Sreeman Nanduri as CTO from 2022-10. The 2022 patent publication concerning AI-based seizure management marked an effort to formalize the technical approach, while the 2023 Digital Health Awards recognition added external visibility. NeuroLiten’s planned expansion from epilepsy into autism, attention disorders, sleep disorders, Parkinson’s disease, and Alzheimer’s disease suggests a platform-oriented growth thesis. As of Oct 7, 2026, the company therefore appears to remain an early-stage venture with technical and platform ambitions but limited publicly evidenced execution at scale.